



October 2018

ELDER CARE

A Resource for Interprofessional Providers

Restless Legs Syndrome

Darlene Moyer, MD, Javier Zayas-Bazan, MD, and Danielle Miller, DO, HonorHealth, Phoenix, AZ

Restless Legs Syndrome (RLS) is a common condition that geriatricians and primary care clinicians can easily manage. This issue of Elder Care will review the most important information needed to diagnose and treat RLS.

What is RLS?

Patients with RLS suffer from a strong urge to move their legs or other body parts. Since the urge is brought on by rest and is worse in the evening, it results in significant sleep disruption and can lead to daytime somnolence and diminished quality of life.

How Common is RLS?

RLS is estimated to affect about 10% of all adults, and up to 25% of those over 65. Older adults with RLS tend to have more severe symptoms than younger people because of the natural progression of the disease.

Diagnostic Criteria

There are no physical exam or lab findings that definitively identify RLS, so expert panels have developed specific clinical criteria to help diagnose the condition. Diagnosis is based on history alone, and there are five “essential criteria” that must be present to make the diagnosis: (1) a strong urge to move the legs or other body parts that (2) is brought on by rest, (3) gets better with activity, (4) gets worse in the evening or night, and (5) cannot be accounted for by another medical or behavioral condition. These essential criteria are partially defined by the URGE mnemonic: U=urge to move, R=rest-induced, G=gets better with activity, and E=evening or night-time accentuation.

In addition to the essential criteria, there are supportive features that are not required but help with diagnosis. They include the presence of periodic limb movements, a response to dopaminergic therapy, family history of RLS, and a lack of expected daytime sleepiness.

RLS can be classified as “chronic-persistent” (untreated symptoms occur \geq twice weekly for a year) or “intermittent” (untreated symptoms that occur less than twice weekly). In addition, RLS can be classified as “clinically significant” or “not clinically significant,” based on the amount of distress and impairment that results.

RLS must be differentiated from other disorders that can have similar symptoms. Table 1 summarizes a few other movement disorders that can be confused with RLS.

Table 1. Some Conditions That Can Mimic RLS	
Condition	What is Different than RLS
Conditions that occur during sleep	
Hypnagogic jerks	Sudden, brief, involuntary jerks of arms or legs, typically at onset of sleep
Sleep-related cramps	Involve specific muscle groups. Relieved (or partially relieved) by stretching
Pain syndromes	
Neuropathic pain	Pain may occur during periods of activity, rather than only during rest
Peripheral vascular disease	Claudication (pain) evoked by activity, rather than by rest
Painful-legs/moving-toes syndrome	Continuous/semi-continuous involuntary toe movement with associated leg pain, usually in patients with spinal cord or foot/leg injuries
Drug-induced syndromes	
Neuroleptic-induced akathisia	Day or nighttime restlessness (in patient taking neuroleptic) that is generalized, immediately relieved with movement, and recurs after stopping movement
Normal positional discomfort	Alleviated by change in body position without need for repetitive body movements

TIPS FOR TREATING RESTLESS LEGS SYNDROME

- Always check a ferritin level in patients with suspected RLS, and give iron therapy if ferritin is <75 μ g/L.
- Recommend non-drug treatment as first-line therapy. It includes good sleep hygiene practices, daytime exercise, and avoiding substances that can aggravate RLS.
- If drug therapy is needed, consider the newer agents, pramipexole and ropinirole, as they are less apt to cause rebound and augmentation than are levodopa/carbidopa.
- Prescribe chronic opioids only for severe cases that don't respond to other treatments.

ELDER CARE

Continued from front page

Secondary Causes

The most common identifiable conditions known to cause RLS include iron deficiency, renal failure, medication side effects and, in younger adults, pregnancy. Screening for these secondary causes with a history, physical, and laboratory exams can eliminate these treatable causes of RLS. Ferritin levels should be checked in all patients with RLS symptoms and iron replacement therapy given if levels are $<75 \mu\text{g/L}$, even if the patient is not anemic. Consider checking TSH, vitamin B12, and vitamin D levels as well. There is also an association between RLS and mood disorders and patients should be screened for these conditions.

Non-Drug Treatments

Non-drug treatment options include instituting good sleep hygiene practices, increased daytime physical exercise, mentally stimulating activities, and avoiding stimulants and other substances that can exacerbate symptoms (Table 2). Patients might also consider trying pneumatic compression devices prior to the typical onset of symptoms.

Drug Treatment

Drug treatment aims to control symptoms and avoid augmentation. First line options include dopamine agonists, and gabapentin-related medications (Figure 1).

A major concern about drug therapy is augmentation, which occurs when patients on dopamine agonists begin to experience RLS symptoms earlier in the day compared to before therapy was started. Augmentation is not, however, associated with the gabapentin-related medications. Augmentation can be managed by switching agents or drug classes, decreasing dose, or implementation of a “drug holiday.”

Alternative drug treatments include chronic opioids. Therapy with these alternative medications must be reserved for severe cases, used with caution in older adults, and individualized to each patient’s comorbidities, and medication tolerance and response. Figure 1 provides a stepwise approach to drug therapy based on symptom frequency and severity.

Antihistamines	Glucocorticoids	Selective serotonin reuptake inhibitors
Caffeine and other stimulants	Anti-emetics	Tricyclic antidepressants
Calcium-channel blockers	Phenothiazines	Nicotine, alcohol

STEP 3 Refractory Symptoms (Changing Therapy)	<ul style="list-style-type: none"> • First: change to a different first-line agent • Next: consider changing to a different dopamine agonist or second-line agent • Also: If augmentation occurs consider a “drug holiday” from dopamine agonists; use gabapentin-related agents or different dopamine agonists in the interim • Finally: consider opioids for severe/resistant cases
STEP 2 Daily Symptoms (Daily Therapy)	<ul style="list-style-type: none"> • First-line treatments (level A evidence per American Academy of Neurology guidelines): <ul style="list-style-type: none"> - dopamine agonists (pramipexole, rotigotine) - gabapentin enacarbil • Second-line treatments (level B evidence per American Academy of Neurology guidelines): <ul style="list-style-type: none"> - other dopamine agonists (ropinerole) - pregabalin
STEP 1 Intermittent Symptoms (As-Needed Therapy)	<ul style="list-style-type: none"> • First-line treatment: non-drug treatment, avoidance of triggering substances, treatment of secondary causes • Second-line treatment: as-needed therapy with dopamine agonist (see step 2)

References and Resources

- Allen R. Restless legs syndrome/W-E disease diagnostic criteria: updated International Restless Legs Syndrome Study Group consensus criteria—history, rationale, description, and significance. *Sleep Med.* 2014; 15:960-873
- Bogan R. Restless Legs Syndrome: A review of diagnosis and management in primary care. *Postgrad Med.* 2013; 125(3): 99-109.
- Garcia-Borreguero D. Guidelines for the first-line treatment of restless legs syndrome/W-E disease, prevention and treatment of dopaminergic augmentation; a combined task force of the IRLSSG, EURLSSG, and RLS-foundation. *Sleep Med.* 2016; 21:1-11.
- Muth CC. JAMA Patient Page. Restless legs syndrome. *JAMA* 2017; 317:780
- Winkelman J., et al. Practice guidelines summary: Treatment of restless legs syndrome in adults. *Neurology.* 2016; 87:2585-2592.

Interprofessional care improves the outcomes of older adults with complex health problems.

Editors: Mindy Fain, MD; Jane Mohler, NP-c, MPH, PhD; and Barry D. Weiss, MD

Interprofessional Associate Editors: Tracy Carroll, PT, CHT, MPH; David Coon, PhD; Marilyn Gilbert, MS, CHES;

Jeannie Lee, PharmD, BCPS; Marisa Menchola, PhD; Francisco Moreno, MD; Linnea Nagel, PA-C, MPAS; Lisa O’Neill, DBH, MPH; Floribella Redondo; Laura Vitkus, MPH

The University of Arizona, PO Box 245027, Tucson, AZ 85724-5027 | (520) 626-5800 | <http://aging.arizona.edu>

Supported by: Donald W. Reynolds Foundation, Arizona Geriatrics Workforce Enhancement Program and the University of Arizona Center on Aging

This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1QHP28721, Arizona Geriatrics Workforce Enhancement Program. This information or content and conclusions are those of the author and